Actively Recruiting
Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia
Led by AstraZeneca · Updated on 2026-03-31
200
Participants Needed
13
Research Sites
147 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Clinical and Demographic Characteristics of Adult Patients with NEurofibromatosis in RUSsia (NEREUS)
CONDITIONS
Official Title
Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 63 18 years at the time of inclusion.
- Signed and dated written informed consent in accordance with ICH-GCP and local law prior to inclusion in the study.
- NF1 diagnosed according to the international consensus criteria.
- Confirmed PN by clinical assessment, ultrasound imaging, MRI, or biopsy; one method is sufficient.
- Presence of PN-associated symptoms.
- Adult patients (63 18 years) with newly diagnosed PN or established PN who have not received MEK-inhibitor therapy for PN, verified by medical records or histories.
You will not qualify if you...
- Participation in any clinical study currently (patients in other non-interventional studies may be included).
- Evidence of malignant glioma, malignant peripheral nerve sheath tumor, or other cancer requiring chemotherapy or radiation therapy.
- Patient unable to return for follow-up visits or obtain required follow-up studies, as judged by the investigator.
- Pregnant or breastfeeding individuals unable to undergo radiographic evaluations or MRI scans needed for research.
- Prior use of any MEK-inhibitor for PN therapy within 4 months before screening or therapy initiation before age 18.
- Patients who change their index pathogenetic therapy regimen during the study will be excluded from primary efficacy analysis and study participation from that point onward.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
Research Site
Arkhangelsk, Russia
Actively Recruiting
2
Research Site
Chelyabinsk, Russia
Actively Recruiting
3
Research Site
Krasnoyarsk, Russia
Actively Recruiting
4
Research Site
Kurgan, Russia
Actively Recruiting
5
Research Site
Moscow, Russia
Actively Recruiting
6
Research Site
Nizhny Novgorod, Russia
Actively Recruiting
7
Research Site
Novosibirsk, Russia
Actively Recruiting
8
Research Site
Orenburg, Russia
Actively Recruiting
9
Research Site
Saint-Peretsburg, Russia
Actively Recruiting
10
Research Site
Samara, Russia
Actively Recruiting
11
Research Site
Tomsk, Russia
Actively Recruiting
12
Research Site
Ufa, Russia
Actively Recruiting
13
Research Site
Yekaterinburg, Russia
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here